Related Experiment Video

Updated: Apr 9, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

850

Treatment of pediatric lymphoma in Japan: Current status and plans for the future

Ryoji Kobayashi1, Shosuke Sunami2, Tetsuo Mitsui3

  • 1Department of Pediatrics, Sapporo Hokuyu Hospital, Sapporo, Japan.

Pediatrics International : Official Journal of the Japan Pediatric Society
|June 23, 2015
PubMed

Insights

Pediatric lymphoma survival rates exceed 80% across subtypes, showing significant improvement. However, further research is needed for refractory cases and to address international treatment disparities, especially for T-cell lymphoblastic lymphoma.

Area of Science:

  • Pediatric Oncology
  • Hematology
  • Clinical Research

Background:

  • Pediatric lymphoma treatment outcomes have significantly improved over the last three decades.
  • Event-free survival (EFS) rates have shown marked progress across various lymphoma subtypes in children.
  • Existing research highlights advancements but also identifies areas requiring further investigation.

Purpose of the Study:

  • To summarize the current state of pediatric lymphoma treatment efficacy.
  • To identify challenges and future research directions in pediatric lymphoma management.
  • To analyze survival data across different lymphoma subtypes and stages.

Main Methods:

  • Retrospective analysis of existing pediatric lymphoma treatment studies.
  • Inclusion of data from international collaborative studies (e.g., ALB-NHL03, B-NHL03, ALCL99).
  • Comparison of event-free survival (EFS) rates based on lymphoma subtype, clinical stage, and treatment groups.

Main Results:

  • Event-free survival (EFS) exceeding 80% has been achieved for most pediatric lymphoma subtypes.
  • Specific EFS rates reported: Hodgkin's lymphoma (81.5%), T-cell lymphoblastic lymphoma (T-LBL) stages III (70.6%) and IV (88.9%), mature B-cell lymphoma (78%-98%), and advanced stage Japanese patients (81%).
  • Refractory or recurrent lymphoma cases still require improved treatment strategies and survival outcomes.

Conclusions:

  • Current pediatric lymphoma treatments demonstrate high efficacy, achieving >80% EFS.
  • Significant challenges remain in treating refractory/recurrent lymphomas and clarifying age-specific treatment differences.
  • International disparities in treatment outcomes, particularly for stage III T-LBL in Japan compared to the US and Europe, necessitate further investigation.

Keywords:
adolescent and young adultchildhoodlymphoma

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.8K
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

674

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
489
Primary Lymphoid Organs01:16

Primary Lymphoid Organs

Primary lymphoid organs are pivotal in the formation, development, and maturation of lymphocytes, the white blood cells that serve as the backbone of our immune system. This crucial function underscores their fundamental role in maintaining our overall health and immunity. The two primary lymphoid organs of prime importance are the red bone marrow and the thymus.
The red bone marrow is a soft, spongy tissue nestled in the interior of long bones such as the humerus and femur. It is the site...
16.8K
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
383
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
2.5K